

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Neuren Pharmaceuticals Limited
ARBN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Richard Treagus
Date of last notice	16 May 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interests
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ul style="list-style-type: none"> • Ordinary shares – direct interest and indirect interest, registered holder Karen E. Treagus ATF <Treagus Family Trust> • Loan Funded Shares – indirect interest; held in trust in accordance with the rules of the Neuren Pharmaceuticals Limited Loan Funded Share Plan by Neuren Trustee Limited, a subsidiary of Neuren Pharmaceuticals Limited.
Date of change	31 August 2016
No. of securities held prior to change	<ul style="list-style-type: none"> • 500,000 Ordinary shares • 40,000,000 Loan Funded Shares • 9,615,385 Equity Performance Rights
Class	Ordinary shares and Equity Performance Rights
Number acquired	9,615,385 Ordinary shares
Number disposed	9,615,385 Equity Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	nil
No. of securities held after change	<ul style="list-style-type: none"> • 10,115,385 Ordinary shares • 40,000,000 Loan Funded Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of 3 year service qualification period for Equity Performance Rights to Ordinary shares.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	Not applicable
--	----------------

+ See chapter 19 for defined terms.